PMID- 28719489
OWN - NLM
STAT- MEDLINE
DCOM- 20190617
LR  - 20220321
IS  - 1540-0514 (Electronic)
IS  - 1073-2322 (Linking)
VI  - 49
IP  - 5
DP  - 2018 May
TI  - Antithrombin III Attenuates AKI Following Acute Severe Pancreatitis.
PG  - 572-579
LID - 10.1097/SHK.0000000000000946 [doi]
AB  - BACKGROUND: Antithrombin III (ATIII), the predominant coagulation factor 
      inhibitor, possesses anti-inflammatory properties and exerts renoprotective 
      effects on renal ischemia-reperfusion injury in animal models. However, the 
      ATIII's protective effects of ATIII on acute kidney injury (AKI) following severe 
      acute pancreatitis (SAP) need to be confirmed. METHODS: We assessed the 
      association between ATIII activities and the incidence of AKI in patients with 
      SAP, and explored therapeutic effects and potential mechanisms of ATIII on kidney 
      injury in sodium taurocholate induced SAP rat model. Rats were intravenously 
      injected with ATIII (500 mug/kg) before or after the induction of SAP. RESULTS: 
      The results demonstrated ATIII did not attenuate pancreatic injury, but 
      significantly ameliorate renal dysfunction and renal histological injury. ATIII 
      administration alleviated renal inflammation response, oxidative stress, and cell 
      apoptosis. Moreover, ATIII attenuated tumor necrosis factor alpha (TNFalpha)-stimulated 
      intercellular cell adhesion molecule 1(ICAM-1) and monocyte chemotactic protein 1 
      (MCP-1) upregulation in cultured renal tubular epithelial cells. CONCLUSION: 
      ATIII appears to ameliorate SAP-induced kidney injury by inhibiting inflammation, 
      oxidative stress, and apoptosis. ATIII supplementation may have a potential 
      prophylactic and therapeutic effect on SAP induced AKI.
FAU - Kong, Yiwei
AU  - Kong Y
AD  - Department of Nephrology, Shanghai Jiao Tong University Affiliated Sixth People's 
      Hospital, Shanghai, China.
FAU - Yin, Jianyong
AU  - Yin J
AD  - Department of Nephrology, Shanghai Jiao Tong University Affiliated Sixth People's 
      Hospital, Shanghai, China.
FAU - Cheng, Dongsheng
AU  - Cheng D
AD  - Department of Nephrology, Shanghai Jiao Tong University Affiliated Sixth People's 
      Hospital, Shanghai, China.
FAU - Lu, Zeyuan
AU  - Lu Z
AD  - Department of Nephrology, Shanghai Jiao Tong University Affiliated Sixth People's 
      Hospital, Shanghai, China.
FAU - Wang, Niansong
AU  - Wang N
AD  - Department of Nephrology, Shanghai Jiao Tong University Affiliated Sixth People's 
      Hospital, Shanghai, China.
FAU - Wang, Feng
AU  - Wang F
AD  - Department of Nephrology, Shanghai Jiao Tong University Affiliated Sixth People's 
      Hospital, Shanghai, China.
FAU - Liang, Mingyu
AU  - Liang M
AD  - Department of Physiology, Medical College of Wisconsin, Milwaukee, Wisconsin.
AD  - Center of Systems Molecular Medicine, Medical College of Wisconsin, Milwaukee, 
      Wisconsin.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Shock
JT  - Shock (Augusta, Ga.)
JID - 9421564
RN  - 0 (Chemokine CCL2)
RN  - 126547-89-5 (Intercellular Adhesion Molecule-1)
RN  - 4Y8F71G49Q (Malondialdehyde)
RN  - 9000-94-6 (Antithrombin III)
RN  - EC 1.15.1.1 (Superoxide Dismutase)
SB  - IM
MH  - Acute Disease
MH  - Acute Kidney Injury/*blood/*drug therapy
MH  - Animals
MH  - Antithrombin III/*therapeutic use
MH  - Apoptosis/drug effects
MH  - Cell Line
MH  - Chemokine CCL2/blood
MH  - Humans
MH  - Incidence
MH  - Intercellular Adhesion Molecule-1/blood
MH  - Male
MH  - Malondialdehyde/blood
MH  - Pancreatitis/*blood/*drug therapy
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Real-Time Polymerase Chain Reaction
MH  - Superoxide Dismutase/blood
EDAT- 2017/07/19 06:00
MHDA- 2019/06/18 06:00
CRDT- 2017/07/19 06:00
PHST- 2017/07/19 06:00 [pubmed]
PHST- 2019/06/18 06:00 [medline]
PHST- 2017/07/19 06:00 [entrez]
AID - 10.1097/SHK.0000000000000946 [doi]
PST - ppublish
SO  - Shock. 2018 May;49(5):572-579. doi: 10.1097/SHK.0000000000000946.